Journal Articles

2020

**HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring during and after a Pandemic**

N. Varma

N. F. Marrouche

L. Aguinaga

C. M. Albert

E. Arbelo

*See next page for additional authors*

Follow this and additional works at: [https://academicworks.medicine.hofstra.edu/articles](https://academicworks.medicine.hofstra.edu/articles)

Part of the Cardiology Commons

**Recommended Citation**

Varma N, Marrouche NF, Aguinaga L, Albert CM, Arbelo E, Choi JI, Chung MK, Conte G, Epstein LM, Varosy PD, . HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring during and after a Pandemic. . 2020 Jan 01; 13(7):Article 7002 [ p.]. Available from: [https://academicworks.medicine.hofstra.edu/articles/7002](https://academicworks.medicine.hofstra.edu/articles/7002). Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.
SPECIAL REPORT

HRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic

Niraj Varma, MA, MD, PhD, FACC, FRCP; Nassir F. Marrouche, MD, FHR; Luis Aguinaga, MD, MBA, PhD, FESC, FACC; Christine M. Albert, MD, MPH, FHR, FACC; Elena Arbelo, MD, MSci, PhD‡; Jong-II Choi, MD, PhD, MHS§; Mina K. Chung, MD, FHR, FACC†; Giulio Conte, MD, PhD‡; Lilas Daghe, MD‡; Laurence M. Epstein, MD, FACC†; Hamid Ghanbari, MD, FACC‡; Janet K. Han, MD, FHR, FACC‡; Hein Heidbuchel, MD, PhD, FESC, FEHRA‡; He Huang, MD, FACC, FESC, FEHRA‡; Dhanunjaya R. Lakireddy, MD, FHR, FACC‡; Tachapong Ngarmukos, MD, FAPHR, FACC§; Andrea M. Russo, MD, FHR, FACC†; Eduardo B. Saad, MD, PhD, FHR, FESC‡; Luis C. Saenz Morales, MD‡; Kristin E. Sandau, PhD, RN‡; Arun Raghav M. Sridhar, MD, MPH, FACC‡; Eric C. Stecker, MD, MPH, FACC‡; Paul D. Varosy, MD, FHR, FACC‡

Key Words: COVID-19 ● pandemic QT interval ● remote monitoring ● telemedicine

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, started in the city of Wuhan late in 2019. Within a few months, the disease spread toward all parts of the world and was declared a pandemic on March 11, 2020. The current healthcare dilemma worldwide is how to sustain the capacity for quality services not only for those suffering from COVID-19 but also for non-COVID-19 patients, all while protecting physicians, nurses, and other allied healthcare workers.

The pandemic poses challenges to electrophysiologists at several levels. Hospitalized patients who are COVID-19-positive may have preexisting arrhythmias, develop new arrhythmias, or be placed at increased arrhythmic risk from therapies for COVID-19. Cardiac arrhythmia incidence in hospitalized patients has been documented in a few published studies, with reported rates of 7.9%1 and 16.7%2 in hospitals in New York City and Wuhan, respectively, and up to 44%3 in patients requiring intensive care. Life-threatening arrhythmias (ventricular tachycardia/ventricular fibrillation) can occur in up to 6% of hospitalized patients with COVID-19 infection.3 There have also been several case reports of atrioventricular block in hospitalized patients, which is otherwise rarely described during viral illness.4,5 Although the residual left ventricular dysfunction and arrhythmic risk are currently unknown, preliminary pathophysiological,6 histological,7 and imaging8 data suggest that severe...
across the front lines of the pandemic. The representation of authors from some of the most severely affected countries, such as China, Spain, Italy, and the United States, is a tribute from our worldwide community to those colleagues who have worked on the front lines of the pandemic.

**MONITORING STRATEGIES DURING A PANDEMIC: HERE TO STAY**

In light of the current pandemic, monitoring strategies should focus on selecting high-risk patients in need of close surveillance and using alternative remote recording devices to preserve personal protective equipment and protect healthcare workers from potential contagious harm.

**Inpatient**

For inpatient monitoring, telemetry is reasonable when there is concern for clinical deterioration (as may be indicated by acute illness, vital signs, or sinus tachycardia), or in patients with cardiovascular risk factors and/or receiving essential QT-prolonging medications. Telemetry is generally not feasible for persons under investigation without concern for arrhythmias or clinical deterioration in those not receiving QT-prolonging drug therapy. In situations in which a hospital’s existing telemetry capacity has been exceeded by patient numbers or when conventional telemetry monitoring is not feasible, such as off-site or nontraditional hospital units, mobile devices may be used, for example, mobile cardiac outpatient telemetry as an adjunctive approach to support inpatient care.11–16 The majority of mobile cardiac outpatient telemetry devices can provide continuous arrhythmia monitoring using a single-lead ECG and allow for real-time and offline analysis of long-term ECG data. Telemetry can be extended using patch monitoring.16,17 Smartphone ECG monitors are wireless and have also been utilized during the current pandemic. Information is limited, however, on how parameters such as QTc measured on a single- (or limited number) lead ECG can reliably substitute for 12-lead ECG information.18,19 In one study, QT was underestimated by smartphone single-lead ECG.20

**Outpatient**

The principles of remote patient management, crossing geographic, social, and cultural barriers, can be extended to outpatient care and are important to maintain continuity of care for non-COVID-19 patients.21–23 Virtual clinics move far beyond simple telephone contacts by integrating information from photos, video, mobile heart rhythm, and mobile health monitoring devices recording ECG, and remote cardiovascular implantable electronic device (CIED) interrogations.24 A variety of platforms have been developed and used specifically to provide telehealth to patients via video teleconferencing (Table 1). Most healthcare centers have expanded use of telemedicine, with some reporting 100% transformation of in-person clinic visits to telemedicine-based visits to maintain care for non-COVID-19 patients, thus obviating their need to come to the hospital or clinic. This supplements social distancing measures and reduces the risk of transmission, especially for the older and more vulnerable populations. It also becomes a measure to control intake into emergency rooms and outpatient facilities and to permit rapid access when necessary to subspecialists.

Electrophysiology is well placed for virtual consultations. All preobtained data, including ECGs, ambulatory ECG monitoring, cardiac imaging, and coronary angiography can be adequately reviewed electronically. Digital tools such as direct-to-consumer mobile ECG (Table 2) and wireless blood pressure devices can be used to further complement the telehealth visit without in-person contact. CIED, wearable/mobile health, and clinical data can be integrated into clinician workflow.

Additional diagnostic information might be obtained without in-person contact using home enrollment of prescribed ambulatory rhythm monitors. Patch monitors can be mailed to patient homes and easily self-affixed, unlike Holter monitors with cables and electrodes requiring placement by healthcare workers. In some cases, new or follow-up telehealth visits will require an adjunctive in-person visit to perform

---

**Nonstandard Abbreviations and Acronyms**

| CIED | cardiovascular implantable electronic device |
| COVID-19 | coronavirus disease 2019 |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus 2 |
a 12-lead ECG, ECG stress test, echocardiogram, or other diagnostic procedures. Occasionally, conventional clinic visits are required to accurately assess the impact of comorbidities or frailty on procedural risk, or to allow comfortable discussion with multiple family members when planning procedures with high risk. Telephone-only visits (ie, without video) may allow for a broader reach because of ease and ubiquitous accessibility as a communication strategy for immediate access for urgent matters.

There are many barriers to implementation, such as inadequate reimbursement, licensing/regulatory and privacy issues, lack of infrastructure, resistance to change, lack of access/poor internet coverage, restricted financial resources, and limited technical skills (eg, in the elderly patient population). Some telehealth and remote ECG monitoring technologies may be simply unaffordable and/or unavailable, leading to different levels of uptake within communities and across the globe. All stakeholders should collaborate to address these challenges and promote the safe and effective use of digital health during the current pandemic. In recent months, regulations have been eased to permit consults with new patients, issuing prescriptions, and obtaining consents. In that sense, the COVID-19 pandemic may serve as an opportunity to evolve current technologies into indispensable tools for our future cardiological practice.

**THERAPY FOR COVID-19 AND POTENTIAL ELECTRICAL EFFECTS**

No specific cure exists for COVID-19. Potential COVID-19 therapies, especially hydroxychloroquine and azithromycin, are being investigated in ongoing trials but also have been used off label in many parts of the world. These may exert QT-prolonging effects (Table 3) and, since recent observational data have questioned their efficacy, require a careful risk-benefit adjudication. Combination therapy (eg, hydroxychloroquine and azithromycin) may have synergistic effects on QT prolongation. In a retrospective cohort study of 1438 patients with COVID-19 hospitalized in metropolitan New York (ie, a disease epicenter), cardiac arrest was more frequent in patients who received hydroxychloroquine with azithromycin compared with patients who received neither drug. The adjusted hazard ratio for inhospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and for combined hydroxychloroquine and azithromycin was 1.35. However, none of these hazard ratios were statistically significant. The observational design of this study may limit interpretation of these findings. In the absence of clear efficacy data, treatment options should be individualized taking into account their proarrhythmic potential for torsade de pointes, which may be enhanced by concomitant administration of other QT-prolonging drugs (eg, antiarrhythmics, psychotropics, etc).

In COVID-19 patients receiving prior antiarrhythmic therapy, there should be a thorough consideration of risk versus benefit before initiating any QT-prolonging COVID-19 therapies, especially considering their unproven value. For instance, although some recent observational studies highlight adverse effects of hydroxychloroquine in treating this infectious disease, its use is likely to persist outside of randomized trials because of its affordability and global availability compared with, for example, remdesivir. If one of these drugs is judged to be critical, monitoring should be initiated. If life-threatening arrhythmias (ventricular tachycardia/ventricular fibrillation) occur, the benefit of antiarrhythmic drugs, notably amiodarone, outweighs the potential harm of hydroxychloroquine or other QT-prolonging drugs targeting COVID-19, and in these cases antiarrhythmic drugs should be prioritized and used as deemed necessary. Most importantly, all modifiable predisposing factors for QTc prolongation (electrolyte disturbances, drug-to-drug interaction) that may enhance arrhythmia susceptibility should be corrected, and the small subset of individuals with an underlying genetic predisposition such as congenital long QT syndrome (in whom QTc-prolonging medications are contraindicated) should be identified. Additionally, caution must be exercised in case of subclinical or manifest myocarditis that may increase the vulnerability to proarrhythmias associated with QT-prolonging drugs.

If drugs that exert a QT-prolonging effect are to be initiated in an inpatient setting, a baseline 12-lead ECG should be acquired. Following review of the QTc, patients can be stratified into low-risk group (QTc of <500 ms or <550 ms in the setting of wide baseline QRS) or high-risk group (baseline QTc of ≥500 ms or ≥550 ms in the setting of wide baseline QRS, or patients who are started on combination therapies), guiding selection of telemetered versus nonmonitored beds. Low-risk patients treated with QT-prolonging agents may be monitored using MCT (or another available wearable) with twice-a-day transmission of QTc measurements and any urgent alerts. High-risk patients would require more continuous monitoring and follow-up QTc measurements using telemetry preferably (but if unavailable, other remote monitoring devices). A second QTc assessment via telemetry or other remote devices after 2 doses may be helpful in identifying QTc reactors—patients who have an exaggerated response to QT-prolonging agents. An increase in QTc by ≥60 ms or to QTc ≥500 ms on any follow-up QT assessment is considered significant and should prompt a reassessment of risks versus benefits of continuing the drug.

In the outpatient setting, a recent statement from the US Food & Drug Administration (FDA) “cautions against use of hydroxychloroquine or chloroquine for COVID-19
### Table 1. Examples of Commonly Used Platforms for Telehealth\(^{25-27}\)

| Platform | Website |
|----------|---------|
| HIPAA- or PHI-secure telehealth platform | accuRx\(^*\) | [https://www.accurx.com](https://www.accurx.com) |
| | AMD Global Telemedicine\(^†\) | [https://www.amdtelemedicine.com/telemedicine-products/Working-Clinic-Telemedicine.html](https://www.amdtelemedicine.com/telemedicine-products/Working-Clinic-Telemedicine.html) |
| | American Well\(^‡\) | [https://business.amwell.com/solution-overview](https://business.amwell.com/solution-overview) |
| | Attend Anywhere\(^*\) | [https://www.attendanywhere.com](https://www.attendanywhere.com) |
| | BlueJeans for Healthcare\(^‡\) | [https://www.bluejeans.com/use-cases/healthcare](https://www.bluejeans.com/use-cases/healthcare) |
| | Care Connect by KRY/LIVI\(^$\) | [https://www.kry.care](https://www.kry.care) |
| | Caregility\(^‡\) | [https://caregility.com/ue-applications](https://caregility.com/ue-applications) |
| | Cisco Webex\(^†\) | [https://www.webex.com/webxremotehealth.html](https://www.webex.com/webxremotehealth.html) |
| | ClickDoc\(^§\) | [https://www.cgm.com/be/index.fr.jsp](https://www.cgm.com/be/index.fr.jsp) |
| | Conexa Saúde\(∥\) | [https://www.conexasaude.com.br](https://www.conexasaude.com.br) |
| | Docobo\(^*\) | [https://www.docobo.co.uk](https://www.docobo.co.uk) |
| | Doctena\(^§\) | [https://secure.doctena.com](https://secure.doctena.com) |
| | Doctorlink\(^*\) | [https://www.doctornet.com/video-consultation](https://www.doctornet.com/video-consultation) |
| | Doximity\(^‡\) | [https://www.doximity.com](https://www.doximity.com) |
| | Doxy.me\(^‡\) | [https://doxy.me](https://doxy.me) |
| | EMIS Health Video Consult\(^*\) | [https://www.emishealth.com/products/video-consultation](https://www.emishealth.com/products/video-consultation) |
| | Exprivia\(^§\) | [https://www.exprivia.it](https://www.exprivia.it) |
| | FaceTalk\(^§\) | [https://facetalk.nl](https://facetalk.nl) |
| | Google G Suite\(^†\) | [https://gsuite.google.com/industries/healthcare](https://gsuite.google.com/industries/healthcare) |
| | Helena\(^§\) | [https://qa.helena.care](https://qa.helena.care) |
| | Intersysto\(^§\) | [http://www.intersysto.eu](http://www.intersysto.eu) |
| | InTouch Health\(^‡\) | [https://intouchhealth.com/telehealth-solutions](https://intouchhealth.com/telehealth-solutions) |
| | pMD\(^‡\) | [https://www.pmd.com/secure-messaging-telemedicine](https://www.pmd.com/secure-messaging-telemedicine) |
| | Microsoft Teams/Skype for Business E3 and E5\(^†\) | [https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/healthcare-solutions](https://www.microsoft.com/en-us/microsoft-365/microsoft-teams/healthcare-solutions) |
| | Signal\(^¶\) | [https://signal.org](https://signal.org) |
| | Silicon Practice FootFall\(^*\) | [https://www.siliconpractice.co.uk/video-consultations](https://www.siliconpractice.co.uk/video-consultations) |
| | Spruce\(^‡\) | [https://www.sprucehealth.com](https://www.sprucehealth.com) |
| | TeleMedi\(^§\) | [https://telemedi.be](https://telemedi.be) |
| | Updox\(^‡\) | [https://www.updox.com](https://www.updox.com) |
| | US Department of Veterans Affairs Video Connect\(^‡\) | [https://www.mobile.va.gov/app/va-video-connect](https://www.mobile.va.gov/app/va-video-connect) |
| | vSee\(^‡\) | [https://vsee.com](https://vsee.com) |
| | Zoom for Healthcare\(^†\) | [https://zoom.us/healthcare](https://zoom.us/healthcare) |

Proprietary EMR telehealth platforms

Video-conferencing platforms (not HIPAA- or PHI-secure)

| Platform | Website |
|----------|---------|
| GoToMeeting |  |
| Skype |  |
| Zoom |  |

Nonpublic-facing mobile communication platforms (not HIPAA- or PHI-secure)

| Platform | Website |
|----------|---------|
| Apple FaceTime |  |
| Google Duo |  |
| Google Hangouts |  |
| WhatsApp |  |

EMR indicates electronic medical record; HIPAA, Health Insurance Portability and Accountability Act; and PHI, protected health information.

\(^*\)United Kingdom.

\(^†\)Global.

\(^‡\)United States.

\(^§\)Europe.

\(∥\)South America—Brazil.

\(^¶\)Encrypted, but not specifically a telehealth platform.
### Table 2. Examples of Remote ECG and Heart Rate Monitoring Devices

| Device               | Type                  | CE Mark | FDA Clearance | Additional Features/Notes | Website                                      |
|----------------------|-----------------------|---------|---------------|---------------------------|----------------------------------------------|
| **Handheld devices** |                       |         |               |                           |                                              |
| AliveCor KardiaMobile| Wireless              | Yes     | Yes           | FDA cleared for AF (1-lead) and for QTc (6 L) for COVID-19 patients on HCQ±AZM | [https://www.alivecor.com/kardiamobile](https://www.alivecor.com/kardiamobile) |
| Beurer ME 90         | Wireless              | Yes     | No            |                           | [https://www.beurer.com/web/gb/products/medical/ecg-and-pulse-oximeter/mobile-ecg-device/me-90-bluetooth.php](https://www.beurer.com/web/gb/products/medical/ecg-and-pulse-oximeter/mobile-ecg-device/me-90-bluetooth.php) |
| Cardiac Designs ECG  | Wireless              | Yes     | Yes           |                           | [https://www.cardiacdesigns.com](https://www.cardiacdesigns.com) |
| CardioComm Solutions | Wireless              | Yes     | Yes           |                           | [https://www.theheartcheck.com](https://www.theheartcheck.com) |
| HeartCheck and ECG Pen| 1-lead ECG            | Yes     | Yes           |                           |                                              |
| COALA                | Wireless              | Yes     | Yes           | Remote lung auscultation  | [https://www.coalalife.com](https://www.coalalife.com) |
| Eko DUO              | Wireless              | Yes     | Yes           | Remote cardiac auscultation/phonocardiogram | [https://www.ekohealth.com](https://www.ekohealth.com) |
| Omron blood pressure+EKG monitor | Wireless | No     | Yes           | United States and Canada only | [https://omronhealthcare.com](https://omronhealthcare.com) |
| EKGGraph             | Wireless              | No      | Yes           | United States             | [https://sonohealth.org](https://sonohealth.org) |
| **Mobile cardiac telemetry devices** | | | | | |
| CardioQardioCore     | Chest strap           | Yes     | No            | ECG, HR, HRV, RR, activity | [https://www.getqardio.com/qardiocore-wearable-ecg-ekg-monitor-iphone](https://www.getqardio.com/qardiocore-wearable-ecg-ekg-monitor-iphone) |
| BardyDx CAM          | Patch 1-lead ECG      | Yes     | Yes           | Under clinical investigation for QTc monitoring in COVID-19 patients | [https://www.bardydx.com](https://www.bardydx.com) |
| BioTel Heart         | Patch 1-lead ECG      | Yes     | Yes           | FDA cleared for QTc monitoring | [https://www.myheartmonitor.com/device/mcot-patch](https://www.myheartmonitor.com/device/mcot-patch) |
| BodyGuardian MINI Family/BodyGuardian MINI PLUS | Wireless, Patch: 1-lead ECG/Wired, 3-lead ECG | Yes | Yes | ECG, HR, HRV, RR | [https://www.preventicesolutions.com/hcp/bodyguardian-mini-family](https://www.preventicesolutions.com/hcp/bodyguardian-mini-family) |
| iRhythm Zio patch/ Zio AF | Patch 1-lead ECG | Yes | Yes | | [https://www.irhythmtech.com](https://www.irhythmtech.com) |
| InfoBionic MoMe Kardia | Wired 3-lead ECG     | Yes     | Yes           | Remote lung auscultation  | [https://infobionic.com](https://infobionic.com) |
| MedibioSense MBS HealthStream, VitalPatch, MCT | Patch 1-lead ECG | Yes | Yes | Monitors up to 8 vital signs | [https://www.medibiosense.com](https://www.medibiosense.com) |
| MEMO Patch           | Patch/watch           | No      | No            | Asia; Korea FDA approved  | [https://www.huinno.com](https://www.huinno.com) |
| Medilynx PocketECG   | Wired 3-lead ECG      | Yes     | Yes           | HRV                        | [https://www.pocketecg.com](https://www.pocketecg.com) |
| RhythmMedix RhythmStar | Wired 3-lead ECG     | No      | Yes           |                           | [https://www.rhythmmedix.com](https://www.rhythmmedix.com) |
| Samsung S-patch Cardio | Patch 1-lead ECG     | Yes     | No            | Asia; Korea FDA approved  | [https://www.samsungsds.com/global/en/solutions/off/cardio/cardio.html](https://www.samsungsds.com/global/en/solutions/off/cardio/cardio.html) |
| **Smartwatches**     |                       |         |               |                           |                                              |
| Apple Watch          | 1-lead ECG            | Yes     | Yes           | FDA cleared for AF notification | [https://www.apple.com/watch](https://www.apple.com/watch) |
| Withings Move ECG    | 1-lead ECG            | Yes     | No            | Requires Health Mate app for ECG analysis/AF detection | [https://www.withings.com/us/en/move-ecg](https://www.withings.com/us/en/move-ecg) |

AF indicates atrial fibrillation; AZM, azithromycin; BP, blood pressure; FDA, Food & Drug Administration; HCG, hydroxychloroquine; HR, heart rate; HRV, heart rate variability; and RR, respiratory rate.
outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. (This does not affect FDA-approved uses for malaria, lupus, and rheumatoid arthritis.) Exceptions to this practice are acknowledged to occur in some regions, as these drugs have been used outside the United States without regulatory warnings. Under these conditions, or when these drugs are maintained after hospital discharge, consumer mobile ECG devices capable of generating QTc measurements may be used. If the QTc increases significantly, physicians can consider a change or discontinuation of medication via the phone or virtual medical services.

### Electrocardiographic Monitoring During Clinical Trials

Several double- and multi-arm blind randomized controlled trials are underway worldwide for COVID-19 outpatients utilizing different medications that may prolong the QT interval. These drugs are being tested either alone or in various combinations and are being compared with one another, with differential dosing regimens and/or placebo. These drugs are also being tested for post-exposure prophylaxis in high-risk groups.

Mobile health using smartphone-based portable ECG devices as QTc monitoring tools is an innovative and economical solution to conduct monitoring in outpatient trials. For instance, in one trial evaluating hydroxychloroquine and azithromycin (hydroxychloroquine alone and hydroxychloroquine/azithromycin combination) against a placebo, participants receive remote training to acquire a 6-lead ECG at baseline and then at specified follow-up intervals through the trial period (Figure). These ECGs are transmitted to a remote QTc monitoring site, where the QTc is assessed and monitored over the treatment period.

### Table 3. Effect on QTc and Proarrhythmia of Experimental Pharmacological Therapies for COVID-19

| Drug                        | QTc Prolongation | TdP Risk |
|-----------------------------|------------------|----------|
| Chloroquine                | Moderate ↑       | Low risk of TdP |
| Hydroxychloroquine         | Moderate ↑       | Low risk of TdP |
| Azithromycin               | Moderate ↑       | Very low risk of TdP |
| Lopinavir/ritonavir         | Moderate ↑       | Low risk of TdP |
| Tocilizumab                | Mild ↑ or ↓      | NR       |
| Fingolimod                 | Mild ↑           | NR       |
| Remdesivir                 | NR               | NR       |
| Interferon alfacon-1       | NR               | NR       |
| Ribavirin                  | NR               | NR       |
| Methylprednisolone         | NR               | NR       |

NR indicates not reported; and TdP, torsade de pointes.

### THE FUTURE: DIGITAL MEDICINE CATALYZED BY THE PANDEMIC

The COVID-19 public health emergency has forced changes to traditional norms of health care access and delivery across all continents. It has accelerated adoption of telemedicine and all aspects of digital health, regarded as a positive development. Today’s new reality will likely define medicine going forward. Many monitoring and diagnostic testing aspects of both inpatient and outpatient care will be increasingly served by digital medicine tools.

The need for contactless monitoring for inpatients triaged to intensive care unit, telemetry, or nonconventional environments, as well as for outpatients needing continued management, has triggered novel implementation of digital health monitoring tools. Some centers have created algorithms based on predictive analytics of electronic medical record data. Centralized monitoring or mobile continuous monitoring has improved patient outcomes, reduced manpower needs, and is being utilized more commonly. The use of wearables such as watches, smartphones, and smart beds (with elimination of cables and skin electrodes) for in-hospital telemetry is a novel approach. This type of wireless monitoring may be continued after discharge, permitting prolonged surveillance of rhythm and other physiological parameters. Bracelet technologies may transmit multiple parameters (eg, heart rate, sleep, oxygen desaturation index, blood pressure) via a smartphone link to centralized hubs. These technologies provide a solution for intensive monitoring extending beyond the hospital environment.

Outpatient management has been revolutionized since the start of the pandemic. Social distancing measures and restricted clinic access have driven the rapid adoption of telehealth mechanisms to continue management of non-COVID-19 patients. Virtual visits that have been used for decades to reach isolated communities, but less commonly utilized in advanced health systems, have now become the mainstay of ambulatory care across all subspecialties. The initial experience appears to have been positive for both patient and caregiver. Heart rhythm professionals are fortunate to have a choice of wireless technologies to relay monitored information to maintain connection. Wearable and smartphone-based devices allow convenient real-time monitoring for arrhythmias on a long-term basis because of the comfort associated with their small size and ease of use while reducing patient and healthcare worker exposure. Remote CIED monitoring has existed for decades. It is strongly endorsed by professional societies, but in practice only a fraction of its diagnostic and therapeutic capabilities has been utilized—until now. Since the start of the pandemic, utilization of wireless communication with CIEDs has grown exponentially, permanently altering the future of device follow-up. Patient outcomes may be improved.
with intensive device-based monitoring compared with traditional in-clinic evaluations at regular intervals. Recent data indicate that in-person CIED evaluation can be extended safely to at least biennially when daily digital connectivity is maintained. Remote monitoring has the potential advantage of detecting and alerting caregivers (and in the future—patients directly) about important parameter changes, enabling earlier patient hospitalization, even during a presymptomatic phase.

Connectivity permits longitudinal follow-up, with advantages ranging from individual disease management to assessment of penetration of recommended therapies into communities. The ability for CIED remote monitoring data to be streamed to or accessed by multiple providers can facilitate communication and cooperative treatment and should be encouraged. This will require approval by patients, regulators, and manufacturers. Lessons learned from implantable devices can be applied widely in telemedicine. Regulatory bodies have been responsive, for example, approving smartphone-based QT interval measurement and telehealth services across state lines in the United States. The pandemic experience should serve as an impetus to expedite the resolution of persistent challenges, such as validation of digital technologies, infrastructure for data management (and mechanism for relay to patient and caregiver), interoperability with electronic medical record, application of predictive analytics, cybersecurity (and with it the capability for limited forms of remote CIED programming), and reimbursement.

In summary, the crisis precipitated by the pandemic has catalyzed the adoption of remote patient management across many specialties and for heart rhythm professionals, in particular. This practice is here to stay—it will persist even if other less arrhythmogenic treatment strategies evolve for COVID-19 and after the pandemic has passed. This is an opportunity to embed and grow remote services in everyday medical practice worldwide.
43. Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int. 2018;2018:1574886. doi:10.1155/2018/1574886

44. US Food and Drug Administration. ZITHROMAX (azithromycin) for IV infusion only. Highlights of prescribing information. Reference ID: 4051690. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050733s043lbl.pdf. Accessed May 20, 2020.

45. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890. doi: 10.1056/NEJMo1003833

46. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33:303–314. doi: 10.2165/11531850-000000000-00000

47. Cheng XJ, Nie XY, Chen XM, Lin XX, Tang K, Zheng W, Mei WY, Liu LJ, Long M, Yao FJ, et al. The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. J Am Coll Cardiol. 2015;66:2173–2184. doi: 10.1016/j.jacc.2015.09.029

48. Maisch NM, Kochupurackal JG, Sin J. Azithromycin and the risk of cardiovascular complications. J Pharm Pract. 2014;27:496–500. doi: 10.1177/0897190013516503

49. Grange S, Schmitt C, Banken L, Kuhn B, Zhang X. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther. 2011;49:648–655. doi: 10.1041/cp201549

50. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Cardiovascular Risk. J Am Coll Cardiol. 2010;33:303–314. doi: 10.1056/NEJMoa1003833

51. US Food & Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or Accessed April 29, 2020.

52. ClinicalTrials.gov. COVID-19 clinical trials. https://clinicaltrials.gov/ct2/show/NCT04328961?term=Intr&cond=COVID+19&map_cnty=US&map_state=US%3AWA&display=2. Accessed April 26, 2020.

53. ClinicalTrials.gov. ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial). https://clinicaltrials.gov/ct2/show/NCT04352933?term=Intr&cond=COVID+19&display=2. Accessed April 26, 2020.

54. Cantillon DJ, Loy M, Burkle A, Pengel S, Brosovich D, Hamilton A, Khot UN, Lindsay BD. Association Between Off-site Central Monitoring Using Standardized Cardiac Telemetry and Clinical Outcomes Among Non-Critically Ill Patients. JAMA. 2016;316:519–524. doi:10.1001/jama.2016.10258

55. Bagchi S. Telemedicine in rural India. PLoS Med. 2006;3:e82. doi: 10.1371/journal.pmed.0030082

56. Slotwiner D, Varma N, Akar JG, Mannas G, Beardsall M, Fogel RL, Galizio NO, Glober TV, Leahy RA, Love CJ, et al. HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm. 2015;12:e69–100. doi: 10.1016/j.hrthm.2015.05.008

57. Cantillon DJ, Loy M, Burkle A, Pengel S, Brosovich D, Hamilton A, Khot UN, Lindsay BD. Association Between Off-site Central Monitoring Using Standardized Cardiac Telemetry and Clinical Outcomes Among Non-Critically Ill Patients. JAMA. 2016;316:519–524. doi:10.1001/jama.2016.10258

58. Varma N, Epstein AE, Irupen A, Schweikert R, Love C, TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST). Eur Heart J. 2017;38:1749–1755. doi: 10.1093/eurheartj/ehx015

59. Watanabe E, Yamazaki F, Goto T, Asai T, Yamamoto T, Hirooka K, Sato T, Kasai A, Ueda M, Yamakawa T, et al. Remote Monitoring of Pacemaker Patients With Biennial In-Clinic Evaluation: Continuous Home Monitoring in the Japanese At-Home Study: A Randomized Clinical Trial. Circ Arrhythm Electrophysiol. 2020;13:009007. DOI: 10.1161/CIRCEP.120.009007 September 2020
### Appendix 1. Author Disclosure Table

| Writing Group Member | Employment | Honoraria/Speaking/Consulting | Speakers’ Bureau | Research* | Fellowship Support* | Ownership/Partnership/Principal Stockholder | Stock or Stock Options | Intellectual Property/Royalties | Other |
|----------------------|------------|------------------------------|------------------|-----------|-------------------|---------------------------------------------|------------------------|-------------------------------|-------|
| Niraj Varma, MA, MD, PhD, FACC, FRCP (Chair) | Cleveland Clinic, Cleveland, OH | 1: BIOTRONIK; 1: EP Solutions; 1: Medtronic; 1: MicroPort | None | 1: Boston Scientific; 2: Abbott | None | None | None | None | None |
| Nassir F. Marrouche, MD, FHRS (Vice-Chair) | Tulane University School of Medicine, New Orleans, LA | 0: Biosense Webster; 0: BIOTRONIK; 0: Cardiac Design; 0: Medtronic; 1: Preventice | None | 0: Abbott; 0: Boston Scientific; 0: GE Healthcare; 5: Biosense Webster | None | None | None | None | None |
| Luis Aguinaga, MD, MBA, PhD, FESC, FACC | Centro Privado de Cardiología, Tucuman, Argentina | None | None | None | None | None | None | None | None |
| Christine M. Albert, MD, MPH, FHRS, FACC | Cedars-Sinai Medical Center, Los Angeles, CA | 1: Roche Diagnostics | None | 5: Abbott; 5: NIH; 5: Roche Diagnostics | None | None | None | None | None |
| Elena Arbelo, MD, MSci, PhD | Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain | 1: Biosense Webster | None | None | None | None | None | None | None |
| Jong-il Choi, MD, PhD, MHS | Korea University Medical Center, Seoul, Republic of Korea | None | None | None | None | None | None | None | None |
| Mina K. Chung, MD, FHRS, FACC | Cleveland Clinic, Cleveland, OH | 2: ABIM | None | 5: AHA; 5: NIH | None | None | None | None | 1: Elsevier; 1: UpToDate |

(Continued)
| Writing Group Member | Employment | Honoraria/Speaking/Consulting | Speakers’ Bureau | Research* | Fellowship Support* | Ownership/Partnership/Principal/ Majority Stockholder | Stock or Stock Options | Intellectual Property/ Royalties | Other |
|----------------------|------------|-----------------------------|------------------|-----------|---------------------|------------------------------------------------------|-----------------------|-----------------------------|-------|
| Giulio Conte, MD, PhD | Cardiocentro, Lugano, Switzerland | None | None | None | 5: Boston Scientific; 5: Swiss National Science Foundation | None | None | None | None |
| Lilas Dagher, MD | Tulane University School of Medicine, New Orleans, LA | None | None | None | None | None | None | None | None |
| Laurence M. Epstein, MD, FACC | Northwell Health, North Shore University Hospital, Manhasset, NY | None | None | None | None | None | None | None | 2: Boston Scientific (Clinical Events Committee) |
| Hamid Ghanbari, MD, FACC | University of Michigan, Ann Arbor, MI | None | None | None | 1: BIOTRONIK, 1: Boston Scientific, 1: Medtronic, 1: Toyota | None | None | None | None |
| Janet K. Han, MD, FHR, FACC | VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA | None | None | None | None | None | None | None | None |
| Hein Heidbuchel, MD, PhD, FESC, FEHRA | Antwerp University and University Hospital, Antwerp, Belgium | None | None | None | None | None | None | None | None |
| He Huang, MD, FACC, FESC, FEHRA | Renmin Hospital of Wuhan University, Wuhan, China | None | None | None | None | None | None | None | None |
| Dhanunjaya R. Lakireddy, MD, FHR, FACC | Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, KA | 1: BIOTRONIK, 2: Abbott | None | None | None | None | None | None | None |
| Tachapong Ngarmukos, MD, FAPHR, FACC | Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand | 1: Abbott; 1: Bayer; 1: Biosense Webster; 1: BIOTRONIK; 1: Boehringer Ingelheim; 1: Boston Scientific; 1: Daiichi Sankyo; 1: Medtronic; 1: Pfizer | None | None | None | None | None | None | None |
| Andrea M. Russo, MD, FHR, FACC | Cooper Medical School of Rowan University, Camden, NJ | None | None | None | None | None | None | None | 1: UpToDate |

(Continued)
### Appendix 1. Author Disclosure Table Continued

| Writing Group Member | Employment | Honoraria/ Speaking/ Consulting | Speakers’ Bureau | Research* | Fellowship Support* | Ownership/ Partnership/ Principal/ Majority Stockholder | Stock or Stock Options | Intellectual Property/ Royalties | Other |
|---------------------|------------|---------------------------------|-----------------|-----------|--------------------|------------------------------------------------------|------------------------|----------------------------------|-------|
| Eduardo B. Saad, MD, PhD, FHRS, FESC | Hospital Pró-Cardíaco, Rio de Janeiro, Brazil | 1: Biosense Webster | None | None | None | None | None | None | 1: Abbott (Travel/Entertainment) |
| Luis C. Saenz Morales, MD | CardioInfantil Foundation, Cardiac Institute, Bogota, Colombia | None | None | None | None | None | None | None | None |
| Kristin E. Sandau, PhD, RN | Bethel University, St. Paul, MN | 1: Japanese Association of Cardiovascular Nursing | None | None | None | None | None | None | 1: Patient Safety Authority |
| Arun Raghav M. Sridhar, MD, MPH, FACC | University of Washington, Seattle, WA | None | None | None | None | None | None | None | None |
| Eric C. Stecker, MD, MPH, FACC | Oregon Health & Science University, Portland, OR | None | None | 4: AHA | None | None | None | None | None |
| Paul D. Varosy, MD, FHRS, FACC | VA Eastern Colorado Health Care System and University of Colorado, Aurora, CO | None | None | 4: NIH | None | None | None | None | 0: ACC (Committee Chair); 0: AHA (Committee Member); 0: NCDR (Committee Chair/Member) |

Number value: 0=$0; 1=< $10,000; 2=$10,000 to ≤$25,000; 3=$25,000 to ≤$50,000; 4=$50,000 to ≤$100,000; 5>$100,000. ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; AHA, American Heart Association; NCDR, National Cardiovascular Data Registry; and NIH, National Institutes of Health.

*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.